Validate multi-omics findings at the single-molecule level with Next-Gen Protein Sequencing™

BRANFORD, Conn., March 20, 2025--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company^™, announces participation in an upcoming DNAnexus webinar focused on the role of proteomics in multi-omics research. This discussion will explore how the integration of proteomics data with other omics datasets is driving new discoveries in disease research, including cancer.

When: March 25, 2025, at 8 a.m. PT/11 a.m. ET

Attendees will learn about:

• The growing impact of proteomics in multi-omics analysis
• Applications for cancer and other disease research
• Technologies and strategies for large-scale discovery and data analysis
• Tools for orthogonal validation of proteins of interest

WHO: Featured speakers include:

• Meredith Carpenter, PhD, Head of Scientific Affairs, Quantum-Si
• Cindy Lawley, PhD, Sr. Director, Population Health Proteomic Sciences, Olink, Thermo Fisher Scientific
• Theresa Wohlever, Sr. Bioinformatics Scientist, DNAnexus

WHERE: Virtual event – registration required.

HOW: To register, please complete the registration form. A confirmation email will be sent upon registration.

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing Company^™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum^® line of instruments enables Next-Gen Protein Sequencing^™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250320735438/en/

Contacts

Investor Contact
Jeff Keyes
Chief Financial Officer
ir@quantum-si.com

Media Contact
Katherine Atkinson
SVP, Commercial Marketing
media@quantum-si.com